CytoSorbents Corporation (CTSO)

[andy55q]

Literature Database
Sepsis Management in Southeast Asia: A Review and Clinical Experience

Mehta Y, Paul R, Rabbani R, Acharya SP, Withanaarachchi UK. Journal of Clinical Medicine 2022; 11(13);3635
06/27/2022
New!Peer Reviewed Published DataReviewSeptic Shock
Link to source
Summary

This review summarizes the literature that focuses on the diagnosis and treatment of sepsis, issues with colistin resistance, the increasing use of chloramphenicol, antibiotic abuse, resource constraints and finally the association of sepsis with COVID-19 in Southeast Asia. A panel of five experts discussed the literature and made the following recommendations:

Data on the incidence of sepsis in this region be collected and shared
The management of sepsis be personalized
Use of conventional approaches and innovative therapeutic alternatives to sepsis management be employed
In particular a personalized approach and innovative therapeutic alternatives such as CytoSorb are highlighted as potential options for the treatment of patients with sepsis in Southeast Asia. CytoSorb is described in detail, along with all the publications on these patients from this region. It is noted that it is now well established that absence of evidence is not evidence of absence. Therefore, adopting a personalized treatment approach wherever and whenever desirable and embracing novel extracorporeal blood purification technologies could further enhance patient outcomes and alleviate the burden of sepsis. In support of this, the authors state that instead of randomized control trials, that real-world evidence be used to show the benefit in determining the potential of CytoSorb for the management of sepsis.